TapImmune (TPIV) In License Agreement with Crucell (CRXL)
More News related to CRXL
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- UBS Upgrades Crucell NV (CRXL) to Buy
- Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
More News related to TPIV
- TapImmune Announces Additional Funding
- SectorWatch.biz: Vaccines Projected as Leading Pharma Growth Driver
- TapImmune, Inc. to be Featured in Small Cap Stock Newsletter QualityStocks Daily
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- TapImmune Signs License Agreement With Crucell N.V.
More News related to FDA
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
TapImmune Inc. (OTCBB: TPIV) announced a license agreement with Crucell N.V. (Nasdaq: CRXL).
Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.
Related Categories
FDAStocks Mentioned
-0.58
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
